

DRUG DISINVESTMENT IS IT NEEDED AND HOW COULD IT WORK?

November 2018
ISPOR Barcelona

Richard Macaulay PhD, Senior Director, Pricing & Market Access PAREXEL Intl, London, UK

Andrew Walker PhD, former Scottish Medicines Consortium, NHS Greater Glasgow and Clyde; Now: Director, Salus Alba

Detlev Parow MD, Head of Health Care Management, DAK Gesundheit, Hamburg, Germany

Bettina Ryll MD PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University, Sweden

PAREXEL
YOUR JOURNEY. OUR MISSION.®

© 2018 PAREXEL INTERNATIONAL CORP.

SPEAKERS AND AGENDA



Richard Macaulay

Senior Director, Pricing & Market Access PAREXEL Intl

Introduction to drug disinvestment



Andrew Walker

Ex-Scottish Medicines Consortium; Current: Director, Salus Alba

UK national HTA perspective



Detlev Parow

Head of Pharmaceutical Department, DAK Gesundheit

DE regional payer perspective



Bettina Ryll

Founder Melanoma Patient Network Europe

Physician & patient perspective

On the need, their experiences, & potential mechanisms for drug disinvestment

Each panelist will speak for 10 minutes and this will be followed by a 20-minute panel discussion, and 10 minutes of Q&A from the audience

© 2018 PAREXEL INTERNATIONAL CORP. / 2

PAREXEL®


INTRODUCTION TO DRUG DISINVESTMENT



*HEALTHCARE COSTS ARE INCREASING WHILST BUDGETS
ARE BEING CONSTRAINED NECESSITATING TRADE-OFFS*




Escalating costs



Budgetary pressures

How can high-cost new therapies be reimbursed
whilst managing the cost of care?

...AND NEW HIGH-COST THERAPY CLASSES WITH TRANSFORMATIONAL PATIENT BENEFITS ARE EMERGING




These therapies are often **very high-cost**, reflective of their patient benefits, manufacturing costs, and small patient populations

DRUG DISINVESTMENT UNDERLIES TWO POTENTIAL KEY APPROACHES TO ADDRESSING THIS...

- 1** Re-allocating funding from already reimbursed treatments deemed to be of low value
- 2** Temporary reimbursement (at a discount) of new treatments until more robust evidence available


...HOWEVER, DESPITE BEING CONCEPTUALLY APPEALING, IN PRACTICE THEY CAN BE CHALLENGING...



© 2018 PAREXEL INTERNATIONAL CORP. / 7

PAREXEL[®]

...AND DISINVESTMENT ATTEMPTS TO DATE HAVE FACED SIGNIFICANT IMPLEMENTATION DIFFICULTIES...



© 2018 PAREXEL INTERNATIONAL CORP. / 8

PAREXEL[®]

...WE WILL ATTEMPT TO ADDRESS THE ISSUE OF DRUG DISINVESTMENT – BOTH ITS NEED & IMPLEMENTATION

DRUG DISINVESTMENT IS IT NEEDED AND HOW COULD IT WORK?

We will hear perspectives from

UK national HTA



Andrew Walker

DE regional payer



Detlev Parow

Physician & patient



Bettina Ryll